PureTech Health plc
NASDAQ:PRTCBiotechnology
+$0.45 today
- Market cap
- $423.09M
- Beta
- 0.79
- P/E (TTM)
- -0.4
- EPS (TTM)
- -$45.37
Volume 0.01M
Average 0.01M
PRTC Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
PureTech Health plcNASDAQ: PRTC
Short-term Investments · Q4 FY2025 · quarter ended Dec 2025
Short-term investments falls 71.4% from a year ago
Short-term investments stood at $24.83M at the end of Q4 FY2025, down 71.4% from a year earlier. Over 3 fiscal years it compounded at -50.1% a year.
Context
- Short-term investments amounted to 4.6% of total assets at the end of Q4 FY2025, down 9.7 pp from a year earlier.
- Short-term investments increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps falling in the next quarterly balance sheet after a -71.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 24.83M USD
- Year-over-year change
- -71.4%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.83M | -71.4% |
| FY2024 | 2024-12-31 | 86.67M | -36.3% |
| FY2023 | 2023-12-31 | 136.06M | -32.0% |
| FY2022 | 2022-12-31 | 200.23M | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Investments vs competitors
How PRTC compares with its peers on the latest reported figures
- PRTC's Dec 2025 short-term investments of $24.83M is the 7th highest of the 11 companies compared; the peer median is $87.36M.
- Its year-over-year change of -71.4% is the 7th highest of 9, against a peer median of -49.8%.
- Short-term investments amounts to 4.6% of total assets for PRTC, versus a peer median of 19.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | Jun 2026 | $438.59M | +31.1% | +48.2% | 78.2% |
| Mar 2026 | $119.02M | -46.3% | — | 45.2% | |
| Mar 2026 | $98.51M | -76.6% | — | 18.7% | |
| Mar 2026 | $94.77M | -64.7% | -19.8% | 33.2% | |
| Mar 2026 | $91.14M | -53.3% | -19.1% | 42.7% | |
| Mar 2026 | $83.58M | -13.2% | +29.9% | 19.8% | |
| Dec 2025 | $24.83M | -71.4% | -50.1% | 4.6% | |
| Mar 2026 | $17.44M | +91700.0% | -31.4% | 15.9% | |
| Mar 2026 | $0 | — | — | 0.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $0 | -100.0% | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding PRTC) | $87.36M | -49.8% | -19.1% | 19.2% | |
Competitors are the stored peer set for PRTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 465.71M | 149.87M | 191.08M | 280.64M | 254.07M |
| Short-term Investments | 0 | 200.23M | 136.06M | 86.67M | 24.83M |
| Net Receivables | 3.59M | 22.36M | 2.38M | 12.9M | 8.13M |
| Inventory | 28M | 0 | 0 | 0 | 0 |
| Other Current Assets | (6.24M) | 2.12M | 13.37M | 1.64M | 11.42M |
| Total Current Assets | 501.81M | 386.19M | 347.2M | 386.26M | 305.02M |
| Property, Plant & Equipment (Net) | 43.94M | 37.24M | 19.36M | 15.13M | 11.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 987K | 831K | 906K | 601K | 601K |
| Long-term Investments | 398.46M | 60.81M | 325.63M | 200.17M | 217.43M |
| Tax Assets | (398.46M) | (60.81M) | 0 | 0 | 0 |
| Other Non-current Assets | 399.27M | 278.39M | 879K | 476K | 166K |
| Total Non-current Assets | 444.2M | 316.45M | 346.77M | 216.38M | 229.69M |
| Total Assets | 946.01M | 702.65M | 693.97M | 602.64M | 534.71M |
| Account Payables | 11.35M | 26.5M | 14.64M | 5.52M | 3.07M |
| Short-term Debt | 5.5M | 7.5M | 3.7M | 4.11M | 4.92M |
| Tax Payables | 57K | 57K | 0 | 75K | 0 |
| Deferred Revenue | 31.32M | 2.19M | (29.47M) | 0 | 0 |
| Other Current Liabilities | 152.01M | 29.4M | 29.64M | 27.18M | 31.7M |
| Total Current Liabilities | 226.14M | 96.89M | 51.37M | 41.39M | 46.31M |
| Long-term Debt | 14.26M | 10.24M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 89.77M | 19.65M | 52.46M | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.66M | 4.13M | 113.66M | 138.64M | 171.64M |
| Total Non-current Liabilities | 135.72M | 58.17M | 184.37M | 153.31M | 182.73M |
| Total Liabilities | 361.86M | 155.06M | 235.74M | 194.7M | 229.03M |
| Common Stock | 5.44M | 5.46M | 5.46M | 4.86M | 4.86M |
| Retained Earnings | 199.87M | 149.52M | 83.82M | 32.49M | 61.28M |
| Accumulated OCI | (39.61M) | (14.39M) | 129.15M | 133.96M | 182K |
| Other Stockholders Equity | 98.9M | 124.12M | 0 | 0 | (3.35M) |
| Minority Interest | (9.37M) | 5.37M | (5.84M) | (6.77M) | (6.4M) |
| Total Equity | 584.15M | 547.59M | 458.23M | 407.93M | 305.68M |
| Total Debt | 52.75M | 46.87M | 25.34M | 22.36M | 19.76M |
| Net Debt | (413.68M) | (102.99M) | (165.74M) | (258.28M) | (234.31M) |
PureTech Health plc
NASDAQ:PRTC
Intrinsic Alpha fair value
Locked
Current Price
$17.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.